Cayman Islands | | | 6770 | | | 98-1541723 |
(State or other jurisdiction of incorporation or organization) | | | (Primary Standard Industrial Classification Code Number) | | | (I.R.S. Employer Identification Number) |
Christian O. Nagler Ross M. Leff Kirkland & Ellis LLP 601 Lexington Avenue New York, New York 10022 Tel: (212) 446 4800 Fax: (212) 446 4900 | | | Gregg A. Noel Michael J. Mies Skadden, Arps, Slate, Meagher & Flom LLP 525 University Avenue, Suite 1400 Palo Alto, California 94301 Tel: (650) 470 4500 Fax: (650) 470 4570 |
Large accelerated filer ☐ | | | Accelerated filer ☐ | | | Non-accelerated filer ☒ | | | Smaller reporting company ☒ |
| | | | | | Emerging growth company ☒ |
Title of Each Class of Securities to be Registered | | | Amount Being Registered | | | Proposed Maximum Offering Price Per Security(1) | | | Proposed Maximum Aggregate Offering Price(1) | | | Amount of Registration Fee |
Class A ordinary shares 0.0001 par value(2)(3) | | | 14,375,000 shares | | | $10.00 | | | $143,750,000 | | | $18,659 |
(1) | Estimated solely for the purpose of calculating the registration fee. |
(2) | Includes 1,875,000 Class A ordinary shares, which may be issued upon exercise of a 45-day option granted to the underwriters to cover over allotments, if any. |
(3) | Pursuant to Rule 416, there are also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from share splits, share dividends or similar transactions. |
| | Per Share | | | Total | |
Public offering price | | | $10.00 | | | $125,000,000 |
Underwriting discounts and commissions(1) | | | $0.55 | | | $6,875,000 |
Proceeds, before expenses, to us | | | $9.45 | | | $118,125,000 |
(1) | Includes $0.35 per share, or $4,375,000 in the aggregate (or $5,031,250 in the aggregate if the underwriters’ over-allotment option is exercised in full), payable to the underwriters for deferred underwriting commissions to be placed in a trust account located in the United States as described herein and released to the underwriters only upon the consummation of an initial business combination. See also “Underwriting” beginning on page 130 for a description of compensation and other items of value payable to the underwriters. |
Jefferies | | | Goldman Sachs & Co. LLC |
| | Page | |
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| | ||
| |
⯀ | “Companies Law” are to the Companies Law (2020 Revision) of the Cayman Islands as the same may be amended from time to time; |
⯀ | “company,” “we,” “us,” “our,” or “our company” are to ARYA Sciences Acquisition Corp III, a Cayman Islands exempted company; |
⯀ | “founders” are to Joseph Edelman, Adam Stone, Michael Altman and Konstantin Poukalov, senior executives of Perceptive Advisors; |
⯀ | “founder shares” are to our Class B ordinary shares initially issued to our sponsor in a private placement prior to this offering and the Class A ordinary shares that will be issued upon the automatic conversion of the Class B ordinary shares at the time of our initial business combination (for the avoidance of doubt, such Class A ordinary shares will not be “public shares”); |
⯀ | “initial shareholders” are to our sponsor and each other holder of founder shares upon the consummation of this offering; |
⯀ | “management” or “our management team” are to our executive officers and directors (including our director nominees who will become directors at the consummation of this offering); |
⯀ | “ordinary shares” are to our Class A ordinary shares and our Class B ordinary shares; |
⯀ | “Perceptive Advisors” are to Perceptive Advisors, LLC, an affiliate of our sponsor; |
⯀ | “private placement shares” are to the Class A ordinary shares to be issued to our sponsor in a private placement simultaneously with the closing of this offering (which private placement shares are identical to the shares sold in this offering, subject to certain limited exceptions as described in this prospectus) and upon conversion of working capital loans; |
⯀ | “public shareholders” are to the holders of our public shares, including our sponsor and management team to the extent our sponsor and/or members of our management team purchase public shares, provided that our sponsor’s and each member of our management team’s status as a “public shareholder” will only exist with respect to such public shares; |
⯀ | “public shares” are to our Class A ordinary shares to be sold in this offering (whether they are purchased in this offering or thereafter in the open market); and |
⯀ | “sponsor” are to ARYA Sciences Holdings III, a Cayman Islands exempted limited company. |
⯀ | have a scientific or other competitive advantage in the markets in which they operate and which can benefit from access to additional capital as well as our industry relationships and expertise; |
⯀ | are ready to be public, with strong management, corporate governance and reporting policies in place; |
⯀ | will likely be well received by public investors and are expected to have good access to the public capital markets; |
⯀ | have significant embedded and/or underexploited growth opportunities; |
⯀ | exhibit unrecognized value or other characteristics that we believe have been misevaluated by the market based on our rigorous analysis and scientific and business due diligence review; and |
⯀ | will offer attractive risk-adjusted equity returns for our shareholders. |
(1) | Founder shares are currently classified as Class B ordinary shares, which shares will automatically convert into Class A ordinary shares at the time of our initial business combination as described below adjacent to the caption “Founder shares conversion and anti-dilution rights” and in our amended and restated memorandum and articles of association. |
(2) | Includes up to 468,750 founder shares that are subject to forfeiture. |
(3) | Assumes no exercise of the underwriters’ over allotment option. |
(4) | Includes 12,500,000 public shares, 450,000 private placement shares and 3,125,000 founder shares, assuming 468,750 founder shares have been forfeited. |
(5) | Unlike other SPAC IPOs, investors in this offering will not receive warrants that would become exercisable following completion of our initial business combination. |
• | only holders of the founder shares have the right to vote on the election of directors prior to the completion of our initial business combination and holders of a majority of our founder shares may remove a member of the board of directors for any reason; |
• | the founder shares are subject to certain transfer restrictions, as described in more detail below; |
• | our sponsor and our management team have entered into an agreement with us, pursuant to which they have agreed to (i) waive their redemption rights with respect to any founder shares, private placement shares and public shares they hold, (ii) to waive their redemption rights with respect to any founder shares, private placement shares and any public shares purchased during or after this offering in connection with a shareholder vote to approve an amendment to our amended and restated memorandum and articles of association (A) that would modify the substance or timing of our obligation to provide holders of our Class A ordinary shares the right to have their shares redeemed in connection with our initial business combination or to redeem 100% of our public shares if we do not complete our initial business combination within 24 months from the closing of this offering or (B) with respect to any other provision relating to the rights of holders of our Class A ordinary shares and (iii) waive their rights to liquidating distributions from the trust account with respect to any founder shares or private placement shares they hold if we fail to consummate an initial business combination within 24 months from the closing of this offering (although they will be entitled to liquidating distributions from the trust account with respect to any public shares they hold if we fail to complete our initial business combination within 24 months from the closing of this offering). If we seek shareholder approval, we will complete our initial business combination only if a majority of the ordinary shares, represented in person or by proxy and entitled to vote thereon, voted at a shareholder meeting are voted in favor of the business combination. In such case, our sponsor and each member of our management team have agreed to vote their founder shares, private placement shares and any public shares purchased during or after this offering in favor of our initial business combination. As a result, |
• | the founder shares will automatically convert into our Class A ordinary shares at the time of our initial business combination as described below adjacent to the caption “Founder shares conversion and anti-dilution rights” and in our amended and restated memorandum and articles of association; and |
• | the founder shares are entitled to registration rights. |
• | the net proceeds of this offering and the sale of the private placement shares not held in the trust account, which will be approximately $1,000,000 in working capital after the payment of approximately $1,000,000 in expenses relating to this offering; and |
• | any loans or additional investments from our sponsor or an affiliate of our sponsor or certain of our officers and directors, although they are under no obligation to advance funds or invest in us, and provided any such loans will not have any claim on the proceeds held in the trust account unless such proceeds are released to us upon completion of our initial business combination. |
• | conduct the redemptions in conjunction with a proxy solicitation pursuant to Regulation 14A of the Exchange Act, which regulates the solicitation of proxies, and not pursuant to the tender offer rules; and |
• | file proxy materials with the SEC. |
• | conduct the redemptions pursuant to Rule 13e-4 and Regulation 14E of the Exchange Act, which regulate issuer tender offers; and |
• | file tender offer documents with the SEC prior to completing our initial business combination which contain substantially the same financial and other information about the initial business combination and the redemption rights as is required under Regulation 14A of the Exchange Act, which regulates the solicitation of proxies. |
• | repayment of up to an aggregate of $300,000 in loans made to us by our sponsor to cover offering-related and organizational expenses; |
• | reimbursement for office space, secretarial and administrative services provided to us by our sponsor, in the amount of $10,000 per month; |
• | reimbursement for any out-of-pocket expenses related to identifying, investigating, negotiating and completing an initial business combination; and |
• | repayment of loans which may be made by our sponsor or an affiliate of our sponsor or certain of our officers and directors to finance transaction costs in connection with an intended initial business combination. Up to $1,500,000 of such loans may be convertible into shares of the post-business combination company at a price of $10.00 per share at the option of the lender. The shares would be identical to the private placement shares. Except for the foregoing, the terms of such loans, if any, have not been determined and no written agreements exist with respect to such loans. |
| | April 2, 2020 | |
Balance Sheet Data: | | | |
Working capital (deficiency) | | | $(4,245) |
Total assets | | | $25,000 |
Total liabilities | | | $4,245 |
Value of Class A ordinary shares subject to possible redemption | | | $— |
Shareholder’s equity | | | $20,755 |
⯀ | a limited availability of market quotations for our securities; |
⯀ | reduced liquidity for our securities; |
⯀ | a determination that our Class A ordinary shares are a “penny stock” which will require brokers trading in our Class A ordinary shares to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities; |
⯀ | a limited amount of news and analyst coverage; and |
⯀ | a decreased ability to issue additional securities or obtain additional financing in the future. |
⯀ | we have a board that includes a majority of “independent directors,” as defined under Nasdaq rules; |
⯀ | we have a compensation committee of our board that is comprised entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities; and |
⯀ | we have independent director oversight of our director nominations. |
⯀ | restrictions on the nature of our investments; and |
⯀ | restrictions on the issuance of securities, each of which may make it difficult for us to complete our initial business combination. |
⯀ | registration as an investment company with the SEC; |
⯀ | adoption of a specific form of corporate structure; and |
⯀ | reporting, record keeping, voting, proxy and disclosure requirements and other rules and regulations that we are currently not subject to. |
⯀ | may significantly dilute the equity interest of investors in this offering, which dilution would increase if the anti-dilution provisions in the Class B ordinary shares resulted in the issuance of Class A ordinary shares on a greater than one-to-one basis upon conversion of the Class B ordinary shares; |
⯀ | may subordinate the rights of holders of Class A ordinary shares if preference shares are issued with rights senior to those afforded our Class A ordinary shares; |
⯀ | could cause a change in control if a substantial number of our Class A ordinary shares are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors; |
⯀ | may have the effect of delaying or preventing a change of control of us by diluting the share ownership or voting rights of a person seeking to obtain control of us; and |
⯀ | may adversely affect prevailing market prices for our Class A ordinary shares. |
⯀ | default and foreclosure on our assets if our operating revenues after an initial business combination are insufficient to repay our debt obligations; |
⯀ | acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant; |
⯀ | our immediate payment of all principal and accrued interest, if any, if the debt is payable on demand; |
⯀ | our inability to obtain necessary additional financing if the debt contains covenants restricting our ability to obtain such financing while the debt is outstanding; |
⯀ | our inability to pay dividends on our Class A ordinary shares; |
⯀ | using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our Class A ordinary shares if declared, expenses, capital expenditures, acquisitions and other general corporate purposes; |
⯀ | limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate; |
⯀ | increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; and |
⯀ | limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy and other purposes and other disadvantages compared to our competitors who have less debt. |
⯀ | solely dependent upon the performance of a single business, property or asset; or |
⯀ | dependent upon the development or market acceptance of a single or limited number of products, processes or services. |
⯀ | the history and prospects of companies whose principal business is the acquisition of other companies; |
⯀ | prior offerings of those companies; |
⯀ | our prospects for acquiring an operating business at attractive values; |
⯀ | a review of debt-to-equity ratios in leveraged transactions; |
⯀ | our capital structure; |
⯀ | an assessment of our management and their experience in identifying operating companies; |
⯀ | general conditions of the securities markets at the time of this offering; and |
⯀ | other factors as were deemed relevant. |
⯀ | costs and difficulties inherent in managing cross-border business operations; |
⯀ | rules and regulations regarding currency redemption; |
⯀ | complex corporate withholding taxes on individuals; |
⯀ | laws governing the manner in which future business combinations may be effected; |
⯀ | exchange listing and/or delisting requirements; |
⯀ | tariffs and trade barriers; |
⯀ | regulations related to customs and import/export matters; |
⯀ | local or regional economic policies and market conditions; |
⯀ | unexpected changes in regulatory requirements; |
⯀ | longer payment cycles; |
⯀ | tax issues, such as tax law changes and variations in tax laws as compared to the United States; |
⯀ | currency fluctuations and exchange controls; |
⯀ | rates of inflation; |
⯀ | challenges in collecting accounts receivable; |
⯀ | cultural and language differences; |
⯀ | employment regulations; |
⯀ | underdeveloped or unpredictable legal or regulatory systems; |
⯀ | corruption; |
⯀ | protection of intellectual property; |
⯀ | social unrest, crime, strikes, riots and civil disturbances; |
⯀ | regime changes and political upheaval; |
⯀ | terrorist attacks, natural disasters and wars; and |
⯀ | deterioration of political relations with the United States. |
⯀ | our ability to select an appropriate target business or businesses; |
⯀ | our ability to complete our initial business combination; |
⯀ | our expectations around the performance of a prospective target business or businesses; |
⯀ | our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination; |
⯀ | our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination; |
⯀ | our potential ability to obtain additional financing to complete our initial business combination; |
⯀ | our pool of prospective target businesses; |
⯀ | our ability to consummate an initial business combination due to the uncertainty resulting from the recent COVID-19 pandemic; |
⯀ | the ability of our officers and directors to generate a number of potential business combination opportunities; |
⯀ | our public securities’ potential liquidity and trading; |
⯀ | the lack of a market for our securities; |
⯀ | the use of proceeds not held in the trust account or available to us from interest income on the trust account balance; |
⯀ | the trust account not being subject to claims of third parties; or |
⯀ | our financial performance following this offering. |
| | Without Over-Allotment Option | | | Over-Allotment Option Exercised | |
| | | | |||
Gross proceeds | | | | | ||
Gross proceeds from Class A ordinary shares offered to public(1) | | | $125,000,000 | | | $143,750,000 |
Gross proceeds from sale of the private placement shares offered in a private placement to the sponsor | | | $4,500,000 | | | $4,875,000 |
Total gross proceeds | | | $129,500,000 | | | $148,625,000 |
Estimated Offering expenses(2) | | | | | ||
Underwriting commissions (2.0% of gross proceeds from shares offered to public, excluding deferred portion)(3) | | | $2,500,000 | | | $2,875,000 |
Legal fees and expenses | | | 325,000 | | | 325,000 |
Printing and engraving expenses | | | 30,000 | | | 30,000 |
Accounting fees and expenses | | | 60,000 | | | 60,000 |
SEC/FINRA Expenses | | | 40,722 | | | 40,722 |
Travel and road show | | | 20,000 | | | 20,000 |
Nasdaq listing and filing fees | | | 55,000 | | | 55,000 |
Director & Officer liability insurance premiums | | | 125,000 | | | 125,000 |
Miscellaneous | | | 344,278 | | | 344,278 |
Total estimated offering expenses (excluding underwriting commissions) | | | $1,000,000 | | | $1,000,000 |
Proceeds after estimated offering expenses | | | $126,000,000 | | | $144,750,000 |
Held in trust account(3) | | | $125,000,000 | | | $143,750,000 |
% of public offering size | | | 100% | | | 100% |
Not held in trust account | | | $1,000,000 | | | $1,000,000 |
| | Amount | | | % of Total | |
Legal, accounting, due diligence, travel, and other expenses in connection with any business combination(6) | | | 350,000 | | | 35.0% |
Legal and accounting fees related to regulatory reporting obligations | | | 150,000 | | | 15.0% |
Consulting, travel and miscellaneous expenses incurred during search for initial business combination target | | | 100,000 | | | 10.0% |
Payment for office space, administrative and support services | | | 240,000 | | | 24.0% |
Nasdaq continued listing fees | | | 55,000 | | | 5.5% |
Working capital to cover miscellaneous expenses and reserves | | | 105,000 | | | 10.5% |
Total | | | $1,000,000 | | | 100.0% |
(1) | Includes amounts payable to public shareholders who properly redeem their shares in connection with our successful completion of our initial business combination. |
(2) | In addition, a portion of the offering expenses have been paid from the proceeds of loans from our sponsor of up to $300,000 as described in this prospectus. To date, we have borrowed approximately $82,000 under the promissory note with our sponsor. These loans will be repaid upon completion of this offering out of the $1,000,000 of offering proceeds that has been allocated for the payment of offering expenses (other than underwriting commissions) and not to be held in the trust account. In the event that offering expenses are less than set forth in this table, any such amounts will be used for post-closing working capital expenses. In the event that the offering expenses are more than as set forth in this table, we may fund such excess with funds not held in the trust account. |
(3) | The underwriters have agreed to defer underwriting commissions of 3.5% of the gross proceeds of this offering. Upon and concurrently with the completion of our initial business combination, $4,375,000, which constitutes the underwriters’ deferred commissions (or $5,031,250 if the underwriters’ over-allotment option is exercised in full) will be paid to the underwriters from the funds held in the trust account. See “Underwriting.” The remaining funds, less amounts |
(4) | These expenses are estimates only. Our actual expenditures for some or all of these items may differ from the estimates set forth herein. For example, we may incur greater legal and accounting expenses than our current estimates in connection with negotiating and structuring our initial business combination based upon the level of complexity of such business combination. In the event we identify a business combination target in a specific industry subject to specific regulations, we may incur additional expenses associated with legal due diligence and the engagement of special legal counsel. In addition, our staffing needs may vary and as a result, we may engage a number of consultants to assist with legal and financial due diligence. We do not anticipate any change in our intended use of proceeds, other than fluctuations among the current categories of allocated expenses, which fluctuations, to the extent they exceed current estimates for any specific category of expenses, would not be available for our expenses. The amount in the table above does not include interest available to us from the trust account. The proceeds held in the trust account will be invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations. Assuming an interest rate of 0.1% per year, we estimate the interest earned on the trust account will be approximately $125,000 per year; however, we can provide no assurances regarding this amount. |
(5) | Assumes no exercise of the underwriters’ over-allotment option. |
(6) | Includes estimated amounts that may also be used in connection with our initial business combination to fund a “no shop” provision and commitment fees for financing. |
| | Without Over-allotment | | | With Over-allotment | |||||||
Public offering price | | | | | $10.00 | | | | | $10.00 | ||
Net tangible book deficit before this offering | | | (0.00) | | | | | (0.00) | | | ||
Increase attributable to public stockholders | | | 1.13 | | | | | 1.00 | | | ||
Pro forma net tangible book value after this offering and the sale of the private placement shares | | | | | 1.13 | | | | | 1.00 | ||
Dilution to public shareholders | | | | | $8.87 | | | | | $9.00 | ||
Percentage of dilution to public shareholders | | | | | 88.7% | | | | | 90.0% |
| | Shares Purchased | | | Total Consideration | | | Average Price Per Share | |||||||
| | Number | | | Percentage | | | Amount | | | Percentage | | |||
Class B Ordinary Shares(1) | | | $3,125,000 | | | 19.44% | | | $25,000 | | | 0.02% | | | $0.008 |
Private Placement Shareholders | | | 450,000 | | | 2.80% | | | 4,500,000 | | | 3.47% | | | $10.00 |
Public Shareholders | | | 12,500,000 | | | 77.76% | | | 125,000,000 | | | 96.51% | | | $10.00 |
| | $16,075,000 | | | 100.00% | | | $129,525,000 | | | 100.00% | | |
(1) | Assumes no exercise of the underwriters’ over-allotment option and the corresponding forfeiture of 468,750 Class B ordinary shares held by our sponsor. |
| | Without Over-allotment | | | With Over-allotment | |
Numerator: | | | | | ||
Net tangible book deficit before this offering | | | $(4,245) | | | $(4,245) |
Net proceeds from this offering and sale of the private placement shares(1) | | | 126,000,000 | | | 144,750,000 |
Plus: Offering costs paid in advance, excluded from tangible book value | | | 25,000 | | | 25,000 |
Less: Deferred underwriting commissions | | | (4,375,000) | | | (5,031,250) |
Less: Proceeds held in trust subject to redemption(2) | | | (116,645,750) | | | (134,739,500) |
| | $5,000,005 | | | $5,000,005 | |
Denominator: | | | | | ||
Ordinary shares outstanding prior to this offering | | | 3,593,750 | | | 3,593,750 |
Ordinary shares forfeited if over-allotment is not exercised | | | (468,750) | | | — |
Ordinary shares offered and sale of private placement shares | | | 12,950,000 | | | 14,862,500 |
Less: Ordinary shares subject to redemption | | | (11,664,575) | | | (13,473,950) |
| | 4,410,425 | | | 4,982,300 |
(1) | Expenses applied against gross proceeds include offering expenses of $1,000,000 and underwriting commissions of $2,500,000 or $2,875,000 if the underwriters exercise their over-allotment option (excluding deferred underwriting fees). See “Use of Proceeds.” |
(2) | If we seek shareholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our sponsor, directors, executive officers, advisors or their affiliates may purchase public shares in privately negotiated transactions or in the open market either prior to or following the completion of our initial business combination. In the event of any such purchases of our shares prior to the completion of our initial business combination, the number of Class A ordinary shares subject to redemption will be reduced by the amount of any such purchases, increasing the pro forma net tangible book value per share. See “Proposed Business — Effecting Our Initial Business Combination — Permitted Purchases and Other Transactions with Respect to Our Securities.” |
| | April 2, 2020 | ||||
| | Actual | | | As Adjusted (1) | |
Note payable - related party(2) | | | $— | | | $— |
Deferred underwriting commissions(3) | | | — | | | 4,375,000 |
Class A ordinary shares, $0.0001 par value, 479,000,000 shares authorized; -0- and 11,664,575 shares are subject to possible redemption, actual and as adjusted, respectively | | | — | | | 116,645,750 |
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding, actual and as adjusted | | | — | | | — |
Class A ordinary shares, $0.0001 par value, 479,000,000 shares authorized; -0- and 1,285,425 shares issued and outstanding (excluding -0- and 11,664,575 shares subject to possible redemption), actual and as adjusted, respectively(4) | | | — | | | 129 |
Class B ordinary shares, $0.0001 par value, 20,000,000 shares authorized, 3,593,750 and 3,125,000 shares issued and outstanding, actual and as adjusted, respectively | | | 359 | | | 313 |
Additional paid-in capital | | | 24,641 | | | 5,003,808 |
Accumulated deficit | | | (4,245) | | | (4,245) |
Total shareholders’ equity | | | $20,755 | | | $5,000,005 |
Total capitalization | | | $20,755 | | | $126,020,755 |
(1) | Assumes no exercise of the underwriters’ over-allotment option and the corresponding forfeiture of 468,750 Class B ordinary shares held by our sponsor. |
(2) | Our sponsor may loan us up to $300,000 under an unsecured promissory note to be used for a portion of the expenses of this offering. To date, we have borrowed approximately $82,000 from our sponsor to cover for expenses in connection with this offering. |
(3) | $0.35 per share, or $4.375 million in the aggregate, will be payable to the underwriters for deferred underwriting commissions. The deferred underwriting commissions will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. The Company records deferred underwriting commissions upon the closing of the initial public offering as a reduction of additional paid-in capital. Since the actual additional paid-in capital was reduced by the recording of the accrued deferred underwriting commission, total capitalization, as adjusted, includes the amount of the deferred underwriting commission to reflect total capitalization. |
(4) | Upon the completion of our initial business combination, we will provide our public shareholders with the opportunity to redeem their public shares for cash at a per share price equal to the aggregate amount then on deposit in the trust account calculated as of two business days prior to the consummation of the initial business combination, including interest earned on the funds held in the trust account and not previously released to us to pay our income taxes, if any, divided by the number of the then-outstanding public shares, subject to the limitations described herein whereby redemptions cannot cause our net tangible assets to be less than $5,000,001 and any limitations (including, but not limited to, cash requirements) created by the terms of the proposed business combination. |
⯀ | may significantly dilute the equity interest of investors in this offering, which dilution would increase if the anti-dilution provisions in the Class B ordinary shares resulted in the issuance of Class A ordinary shares on a greater than one-to-one basis upon conversion of the Class B ordinary shares; |
⯀ | may subordinate the rights of holders of Class A ordinary shares if preference shares are issued with rights senior to those afforded our Class A ordinary shares; |
⯀ | could cause a change in control if a substantial number of our Class A ordinary shares are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors; |
⯀ | may have the effect of delaying or preventing a change of control of us by diluting the share ownership or voting rights of a person seeking to obtain control of us; and |
⯀ | may adversely affect prevailing market prices for our Class A ordinary shares. |
⯀ | default and foreclosure on our assets if our operating revenues after an initial business combination are insufficient to repay our debt obligations; |
⯀ | acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant; |
⯀ | our immediate payment of all principal and accrued interest, if any, if the debt is payable on demand; |
⯀ | our inability to obtain necessary additional financing if the debt contains covenants restricting our ability to obtain such financing while the debt is outstanding; |
⯀ | our inability to pay dividends on our Class A ordinary shares; |
⯀ | using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our Class A ordinary shares if declared, expenses, capital expenditures, acquisitions and other general corporate purposes; |
⯀ | limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate; |
⯀ | increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; and |
⯀ | limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy and other purposes and other disadvantages compared to our competitors who have less debt. |
⯀ | staffing for financial, accounting and external reporting areas, including segregation of duties; |
⯀ | reconciliation of accounts; |
⯀ | proper recording of expenses and liabilities in the period to which they relate; |
⯀ | evidence of internal review and approval of accounting transactions; |
⯀ | documentation of processes, assumptions and conclusions underlying significant estimates; and |
⯀ | documentation of accounting policies and procedures. |
⯀ | have a scientific or other competitive advantage in the markets in which they operate and which can benefit from access to additional capital as well as our industry relationships and expertise; |
⯀ | are ready to be public, with strong management, corporate governance and reporting policies in place; |
⯀ | will likely be well received by public investors and are expected to have good access to the public capital markets; |
⯀ | have significant embedded and/or underexploited growth opportunities; |
⯀ | exhibit unrecognized value or other characteristics that we believe have been misevaluated by the market based on our rigorous analysis and scientific and business due diligence review; and |
⯀ | will offer attractive risk-adjusted equity returns for our shareholders. |
⯀ | subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our initial business combination; and |
⯀ | cause us to depend on the marketing and sale of a single product or limited number of products or services. |
⯀ | we issue (other than in a public offering for cash) ordinary shares that will either (a) be equal to or in excess of 20% of the number of ordinary shares then issued and outstanding (excluding the private placement shares) or (b) have voting power equal to or in excess of 20% of the voting power then issued and outstanding (excluding the private placement shares); |
⯀ | any of our directors, officers or substantial shareholders (as defined by Nasdaq rules) has a 5% or greater interest (or such persons collectively have a 10% or greater interest), directly or indirectly, in the target business or assets to be acquired or otherwise and the present or potential issuance of ordinary shares could result in an increase in outstanding ordinary shares or voting power of 5% or more; or |
⯀ | the issuance or potential issuance of ordinary shares will result in our undergoing a change of control. |
⯀ | the timing of the transaction, including in the event we determine shareholder approval would require additional time and there is either not enough time to seek shareholder approval or doing so would place the company at a disadvantage in the transaction or result in other additional burdens on the company; |
⯀ | the expected cost of holding a shareholder vote; |
⯀ | the risk that the shareholders would fail to approve the proposed business combination; |
⯀ | other time and budget constraints of the company; and |
⯀ | additional legal complexities of a proposed business combination that would be time-consuming and burdensome to present to shareholders. |
⯀ | conduct the redemptions in conjunction with a proxy solicitation pursuant to Regulation 14A of the Exchange Act, which regulates the solicitation of proxies, and not pursuant to the tender offer rules; and |
⯀ | file proxy materials with the SEC. |
⯀ | conduct the redemptions pursuant to Rule 13e-4 and Regulation 14E of the Exchange Act, which regulate issuer tender offers; and |
⯀ | file tender offer documents with the SEC prior to completing our initial business combination which contain substantially the same financial and other information about the initial business combination and the redemption rights as is required under Regulation 14A of the Exchange Act, which regulates the solicitation of proxies. |
| | Redemptions in Connection With Our Initial Business Combination | | | Other Permitted Purchases of Public Shares by Our Affiliates | | | Redemptions if we Fail to Complete an Initial Business Combination | |
Calculation of redemption price | | | Redemptions at the time of our initial business combination may be made pursuant to a tender offer or in connection with a shareholder vote. The redemption price will be the same whether we conduct redemptions pursuant to a tender offer or in connection with a shareholder vote. In either case, our public shareholders may redeem their public shares for cash equal to the aggregate amount then on deposit in the trust account calculated as of two business days prior to the consummation of the initial business combination (which is initially anticipated to be $10.00 per share), including interest earned on the funds held in the trust account and not previously released to us to pay our income taxes, if any, divided by the number of the then-outstanding public shares, subject to the limitation that no redemptions will take place if all of the redemptions would cause our net tangible assets to be less than $5,000,001 and any limitations (including but not limited to cash requirements) agreed to in connection with the negotiation of | | | If we seek shareholder approval of our initial business combination, our sponsor, directors, officers, advisors or their affiliates may purchase shares in privately negotiated transactions or in the open market either prior to or following completion of our initial business combination. There is no limit to the prices that our sponsor, directors, officers, advisors or their affiliates may pay in these transactions. If they engage in such transactions, they will be restricted from making any such purchases when they are in possession of any material nonpublic information not disclosed to the seller or if such purchases are prohibited by Regulation M under the Exchange Act. We do not currently anticipate that such purchases, if any, would constitute a tender offer subject to the tender offer rules under the Exchange Act or a going-private transaction subject to the going-private rules under the Exchange Act ; however, if the purchasers determine at the time of any such purchases that the purchases are subject to such rules, the purchasers will be required | | | If we do not consummate an initial business combination within 24 months from the closing of this offering, we will redeem all public shares at a per-share price, payable in cash, equal to the aggregate amount, then on deposit in the trust account (which is initially anticipated to be $10.00 per share), including interest earned on the funds held in the trust account and not previously released to us to pay our income taxes, if any (less up to $100,000 of interest to pay dissolution expenses) divided by the number of then outstanding public shares. |
| | Redemptions in Connection With Our Initial Business Combination | | | Other Permitted Purchases of Public Shares by Our Affiliates | | | Redemptions if we Fail to Complete an Initial Business Combination | |
| | terms of a proposed business combination. | | | to comply with such rules. | | | ||
| | | | | | ||||
Impact to remaining shareholders | | | The redemptions in connection with our initial business combination will reduce the book value per share for our remaining shareholders, who will bear the burden of the deferred underwriting commissions and taxes payable. | | | If the permitted purchases described above are made, there would be no impact to our remaining shareholders because the purchase price would not be paid by us. | | | The redemption of our public shares if we fail to complete our initial business combination will reduce the book value per share for the shares held by our sponsor, who will be our only remaining shareholder after such redemptions. |
| | Terms of Our Offering | | | Terms Under a Rule 419 Offering | |
Escrow of offering proceeds | | | $125,000,000 of the net proceeds of this offering and the sale of the private placement shares will be deposited into a trust account located in the United States with Continental Stock Transfer & Trust Company acting as trustee. | | | Approximately $106,312,500 of the offering proceeds would be required to be deposited into either an escrow account with an insured depositary institution or in a separate bank account established by a broker-dealer in which the broker-dealer acts as trustee for persons having the beneficial interests in the account. |
| | | | |||
Investment of net proceeds | | | $125,000,000 of the net proceeds of this offering and the sale of the private placement shares held in trust will be invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations. | | | Proceeds could be invested only in specified securities such as a money market fund meeting conditions of the Investment Company Act or in securities that are direct obligations of, or obligations guaranteed as to principal or interest by, the United States. |
| | | | |||
Receipt of interest on escrowed funds | | | Interest income (if any) on proceeds from the trust account to be paid to shareholders is reduced by (i) any income taxes paid or payable and (ii) in the event of our liquidation for failure to complete our initial business combination within the allotted time, up | | | Interest income on funds in escrow account would be held for the sole benefit of investors, unless and only after the funds held in escrow were released to us in connection with our completion of a business combination. |
| | Terms of Our Offering | | | Terms Under a Rule 419 Offering | |
| | to $100,000 of net interest that may be released to us should we have no or insufficient working capital to fund the costs and expenses of our dissolution and liquidation. | | | ||
| | | | |||
Limitation on fair value or net assets of target business | | | Our initial business combination must occur with one or more target businesses that together have an aggregate fair market value of at least 80% of our assets held in the trust account (excluding the amount of deferred underwriting discounts held in trust and taxes payable on the interest earned on the trust account) at the time of signing the agreement to enter into the initial business combination. | | | The fair value or net assets of a target business must represent at least 80% of the maximum offering proceeds. |
| | | | |||
Trading of securities issued | | | The public shares are expected to begin trading on or promptly after the date of this prospectus. If the over-allotment option is exercised following the initial filing of such Current Report on Form 8-K, a second or amended Current Report on Form 8-K will be filed to provide updated financial information to reflect the exercise of the over-allotment option. | | | No trading of the Class A ordinary shares would be permitted until the completion of a business combination. During this period, the securities would be held in the escrow or trust account. |
| | | | |||
Election to remain an investor | | | We will provide our public shareholders with the opportunity to redeem their public shares for cash at a per share price equal to the aggregate amount then on deposit in the trust account calculated as of two business days prior to the consummation of our initial business combination, including interest earned on the funds held in the trust account and not previously released to us to pay our income taxes, if any, divided by the number of the then-outstanding public shares, upon the completion of our initial business combination, subject to the limitations described herein. We may not be required by applicable law or stock exchange rule to hold a shareholder vote. If we are not required by applicable law or stock exchange rule and do not otherwise decide to hold a shareholder vote, we will, pursuant to our amended and restated | | | A prospectus containing information pertaining to the business combination required by the SEC would be sent to each investor. Each investor would be given the opportunity to notify the company in writing, within a period of no less than 20 business days and no more than 45 business days from the effective date of a post-effective amendment to the company’s registration statement, to decide if he, she or it elects to remain a shareholder of the company or require the return of his, her or its investment. If the company has not received the notification by the end of the 45th business day, funds and interest or dividends, if any, held in the trust or escrow account are automatically returned to the shareholder. Unless a sufficient number of investors elect to remain investors, all funds on deposit in the escrow account must be returned to |
| | Terms of Our Offering | | | Terms Under a Rule 419 Offering | |
| | memorandum and articles of association, conduct the redemptions pursuant to the tender offer rules of the SEC and file tender offer documents with the SEC which will contain substantially the same financial and other information about the initial business combination and the redemption rights as is required under the SEC’s proxy rules. If, however, we hold a shareholder vote, we will, like many blank check companies, offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If we seek shareholder approval, we will complete our initial business combination only if a majority of the ordinary shares, represented in person or by proxy and entitled to vote thereon, voted at a shareholder meeting are voted in favor of the business combination. Additionally, each public shareholder may elect to redeem their public shares irrespective of whether they vote for or against the proposed transaction or vote at all. Our amended and restated memorandum and articles of association will require that at least five clear days’ notice will be given of any such shareholder meeting. | | | all of the investors and none of the securities are issued. | |
| | | | |||
Business combination deadline | | | If we do not consummate an initial business combination within 24 months from the closing of this offering, we will (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account and not previously released to us to pay our income taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of the then-outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders | | | If an acquisition has not been completed within 18 months after the effective date of the company’s registration statement, funds held in the trust or escrow account are returned to investors. |
| | Terms of Our Offering | | | Terms Under a Rule 419 Offering | |
| | (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and our board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii) to our obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. | | | ||
| | | | |||
Release of funds | | | Except with respect to interest earned on the funds held in the trust account that may be released to us to pay our income taxes, if any, until the earliest of (i) the completion of our initial business combination, (ii) the redemption of our public shares if we have not consummated an initial business combination within 24 months from the closing of this offering, subject to applicable law and (iii) the redemption of our public shares properly submitted in connection with a shareholder vote to approve an amendment to our amended and restated memorandum and articles of association (A) that would modify the substance or timing of our obligation to provide holders of our Class A ordinary shares the right to have their shares redeemed in connection with our initial business combination or to redeem 100% of our public shares if we do not complete our initial business combination within 24 months from the closing of this offering or (B) with respect to any other provision relating to the rights of holders of our Class A ordinary shares. Based on current interest rates, we expect that interest income earned on the trust account (if any) will be sufficient to pay our income taxes. | | | The proceeds held in the escrow account are not released until the earlier of the completion of a business combination and the failure to effect a business combination within the allotted time. |
Name | | | Age | | | Position |
Joseph Edelman | | | 64 | | | Chairman |
Adam Stone | | | 40 | | | Chief Executive Officer and Director |
Michael Altman | | | 38 | | | Chief Financial Officer and Director |
Konstantin Poukalov | | | 36 | | | Chief Business Officer |
Todd Wider | | | 55 | | | Director Nominee |
⯀ | meeting with our independent registered public accounting firm regarding, among other issues, audits, and adequacy of our accounting and control systems; |
⯀ | monitoring the independence of the independent registered public accounting firm; |
⯀ | verifying the rotation of the lead (or coordinating) audit partner having primary responsibility for the audit and the audit partner responsible for reviewing the audit as required by law; |
⯀ | inquiring and discussing with management our compliance with applicable laws and regulations; |
⯀ | pre-approving all audit services and permitted non-audit services to be performed by our independent registered public accounting firm, including the fees and terms of the services to be performed; |
⯀ | appointing or replacing the independent registered public accounting firm; |
⯀ | determining the compensation and oversight of the work of the independent registered public accounting firm (including resolution of disagreements between management and the independent auditor regarding financial reporting) for the purpose of preparing or issuing an audit report or related work; |
⯀ | establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls or reports which raise material issues regarding our financial statements or accounting policies; |
⯀ | monitoring compliance on a quarterly basis with the terms of this offering and, if any noncompliance is identified, immediately taking all action necessary to rectify such noncompliance or otherwise causing compliance with the terms of this offering; and |
⯀ | reviewing and approving all payments made to our existing shareholders, executive officers or directors and their respective affiliates. Any payments made to members of our audit committee will be reviewed and approved by our board of directors, with the interested director or directors abstaining from such review and approval. |
⯀ | should have demonstrated notable or significant achievements in business, education or public service; |
⯀ | should possess the requisite intelligence, education and experience to make a significant contribution to the board of directors and bring a range of skills, diverse perspectives and backgrounds to its deliberations; and |
⯀ | should have the highest ethical standards, a strong sense of professionalism and intense dedication to serving the interests of the shareholders. |
⯀ | reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer’s compensation, evaluating our Chief Executive Officer’s performance in light of such goals and objectives and determining and approving the remuneration (if any) of our Chief Executive Officer based on such evaluation; |
⯀ | reviewing and approving the compensation of all of our other Section 16 executive officers; |
⯀ | reviewing our executive compensation policies and plans; |
⯀ | implementing and administering our incentive compensation equity-based remuneration plans; |
⯀ | assisting management in complying with our proxy statement and annual report disclosure requirements; |
⯀ | approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our executive officers and employees; |
⯀ | producing a report on executive compensation to be included in our annual proxy statement; and |
⯀ | reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors. |
⯀ | duty to act in good faith in what the director or officer believes to be in the best interests of the company as a whole; |
⯀ | duty to exercise powers for the purposes for which those powers were conferred and not for a collateral purpose; |
⯀ | directors should not improperly fetter the exercise of future discretion; |
⯀ | duty to exercise powers fairly as between different sections of shareholders; |
⯀ | duty not to put themselves in a position in which there is a conflict between their duty to the company and their personal interests; and |
⯀ | duty to exercise independent judgment. |
Individual | | | Entity | | | Entity’s Business | | | Affiliation |
Joseph Edelman | | | Perceptive Advisors, LLC ARYA Sciences Acquisition Corp II | | | Hedge Fund Special Purpose Acquisition Company | | | Chief Executive Officer and Portfolio Manager Chairman |
Adam Stone | | | Perceptive Advisors, LLC Solid Biosciences Renovia Xontogeny Immatics N.V. ARYA Sciences Acquisition Corp II | | | Hedge Fund Pharmaceuticals Healthcare Biotechnology Biotechnology Special Purpose Acquisition Company | | | Chief Investment Officer Director Director Director Director Chief Executive Officer and Director |
Michael Altman | | | Perceptive Advisors, LLC Vitruvius Therapeutics Lyra Therapeutics ARYA Sciences Acquisition Corp II | | | Hedge Fund Pharmaceuticals Healthcare Special Purpose Acquisition Company | | | Managing Director Director Director Chief Financial Officer and Director |
Konstantin Poukalov | | | Perceptive Advisors, LLC Lyra Therapeutics Landos Biopharma, Inc. LianBio | | | Hedge Fund Healthcare Healthcare Healthcare | | | Managing Director Director Director Director |
Todd Wider | | | Abeona Therapeutics, Inc. | | | Pharmaceuticals | | | Director |
| | Emendo Biotherapeutics | | | Biopharmaceuticals | | | Director | |
| | ARYA Sciences Acquisition Corp II | | | Special Purpose Acquisition Company | | | Director |
⯀ | Our executive officers and directors are not required to, and will not, commit their full time to our affairs, which may result in a conflict of interest in allocating their time between our operations and our search for a business combination and their other businesses. We do not intend to have any full-time employees prior to the completion of our initial business combination. Each of our executive officers is engaged in several other business endeavors for which he may be entitled to substantial compensation, and our executive officers are not obligated to contribute any specific number of hours per week to our affairs. |
⯀ | Our sponsor subscribed for founder shares prior to the date of this prospectus and will purchase private placement shares in a transaction that will close simultaneously with the closing of this offering. In July 2020, our sponsor transferred 30,000 founder shares to each of , and Todd Wider. Our sponsor and our management team have entered into an agreement with us, pursuant to which they have agreed to waive their redemption rights with respect to their founder shares, private placement shares and any public shares purchased during or after this offering in connection with (i) the completion of our initial business combination and (ii) a shareholder vote to approve an amendment to our amended and restated memorandum and articles of association (A) that would modify the substance or timing of our obligation to provide holders of our Class A ordinary shares the right to have their shares redeemed in connection with our initial business combination or to redeem 100% of our public shares if we do not complete our initial business combination within 24 months from the closing of this offering or (B) with respect to any other provision relating to the rights of holders of our Class A ordinary shares. Additionally, our sponsor has agreed to waive its rights to liquidating distributions from the trust account with respect to its founder shares if we fail to complete our initial business combination within the required time period. If we do not complete our initial business combination within the required time period, the private placement shares will be worthless. Except as described herein, our sponsor and our management team have agreed not to transfer, assign or sell any of their founder shares until the earliest of (A) one year after the completion of our initial business combination and (B) subsequent to our initial business combination, (x) if the closing price of our Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after our initial business combination, or (y) the date on which we complete a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of our public shareholders having the right to exchange their ordinary shares for cash, securities or other property. With certain limited exceptions, the private placement shares will not be transferable until 30 days following the completion of our initial business combination. Because each of our executive officers and director nominees will own ordinary shares directly or indirectly, they may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination. |
⯀ | Our officers and directors may have a conflict of interest with respect to evaluating a particular business combination if the retention or resignation of any such officers and directors was included by a target business as a condition to any agreement with respect to our initial business combination. |
⯀ | each person known by us to be the beneficial owner of more than 5% of our issued and outstanding ordinary shares; |
⯀ | each of our executive officers, directors and director nominees that beneficially owns ordinary shares; and |
⯀ | all our executive officers and directors as a group. |
Name And Address Of Beneficial Owner(1) | | | Number of Shares Beneficially Owned(2) | | | Approximate Percentage of Outstanding Ordinary Shares | |||
| Before Offering | | | After Offering | |||||
ARYA Sciences Holdings III (our sponsor) | | | 3,485,000(3) | | | 97.2% | | | 21.7%(4) |
Joseph Edelman | | | —(5) | | | —(5) | | | —(5) |
Adam Stone | | | 3,485,000(3) | | | 97.2% | | | 21.7%(4) |
Michael Altman | | | 3,485,000(3) | | | 97.2% | | | 21.7%(4) |
Konstantin Poukalov | | | —(5) | | | —(5) | | | —(5) |
Todd Wider | | | 30,000 | | | * | | | * |
| | 30,000 | | | * | | | * | |
| | 30,000 | | | * | | | * | |
All officers, directors and director nominees as a group ( individuals) | | | 3,575,000 | | | 100% | | | 22.2 |
* | Less than one percent. |
(1) | Unless otherwise noted, the business address of the following entities or individuals is 51 Astor Place, 10th Floor, New York, New York 10003. |
(2) | Interests shown consist solely of founder shares, classified as Class B ordinary shares, and private placement shares. The Class B ordinary shares will automatically convert into Class A ordinary shares at the time of our initial business combination as described in the section entitled “Description of Securities.” |
(3) | The shares reported above are held in the name of our sponsor. Our sponsor is governed by a board of directors consisting of two directors, Messrs. Stone and Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the Class B ordinary shares held of record by our sponsor and may be deemed to have shared beneficial ownership of the Class B ordinary shares held directly by our sponsor. |
(4) | Includes 450,000 private placement shares. |
(5) | Does not include any shares indirectly owned by this individual as a result of his ownership interest in our sponsor. |
⯀ | 12,500,000 Class A ordinary shares issued as part of this offering; |
⯀ | 450,000 private placement shares issued simultaneously with the closing of this offering; and |
⯀ | 3,125,000 Class B ordinary shares held by our initial shareholders. |
⯀ | the founder shares are subject to certain transfer restrictions, as described in more detail below; |
⯀ | our sponsor and our management team have entered into an agreement with us, pursuant to which they have agreed to (i) waive their redemption rights with respect to any founder shares, private placement shares and public shares they hold, (ii) to waive their redemption rights with respect to any founder shares, private placement shares and any public shares purchased during or after this offering in connection with a shareholder vote to approve an amendment to our amended and restated memorandum and articles of association (A) that would modify the substance or timing of our obligation to provide holders of our Class A ordinary shares the right to have their shares redeemed in connection with our initial business combination or to redeem 100% of our public shares if we do not complete our initial business combination within 24 months from the closing of this offering or (B) with respect to any other provision relating to the rights of holders of our Class A ordinary shares and (iii) waive their rights to liquidating distributions from the trust account with respect to any founder shares or private placement shares they hold if we fail to consummate an initial business combination within 24 months from the closing of this offering (although they will be entitled to liquidating distributions from the trust account with respect to any public shares they hold if we fail to complete our initial business combination within 24 months from the closing of this offering); |
⯀ | the founder shares will automatically convert into our Class A ordinary shares at the time of our initial business combination as described below adjacent to the caption “Founder shares conversion and anti-dilution rights” and in our amended and restated memorandum and articles of association; and |
⯀ | the founder shares are entitled to registration rights. |
⯀ | the names and addresses of the members of the company, a statement of the shares held by each member, which: |
⯀ | distinguishes each share by its number (so long as the share has a number); |
⯀ | confirms the amount paid, or agreed to be considered as paid, on the shares of each member; |
⯀ | confirms the number and category of shares held by each member; and |
⯀ | confirms whether each relevant category of shares held by a member carries voting rights under the Articles, and if so, whether such voting rights are conditional; |
⯀ | the date on which the name of any person was entered on the register as a member; and |
⯀ | the date on which any person ceased to be a member. |
⯀ | we are not proposing to act illegally or beyond the scope of our corporate authority and the statutory provisions as to majority vote have been complied with; |
⯀ | the shareholders have been fairly represented at the meeting in question; |
⯀ | the arrangement is such as a businessman would reasonably approve; and |
⯀ | the arrangement is not one that would more properly be sanctioned under some other provision of the Companies Law or that would amount to a “fraud on the minority.” |
⯀ | a company is acting, or proposing to act, illegally or ultra vires (beyond the scope of its authority); |
⯀ | the act complained of, although not beyond the scope of the authority, could be effected if duly authorized by more than the number of votes which have actually been obtained; or |
⯀ | those who control the company are perpetrating a “fraud on the minority.” |
⯀ | annual reporting requirements are minimal and consist mainly of a statement that the company has conducted its operations mainly outside of the Cayman Islands and has complied with the provisions of the Companies Law; |
⯀ | an exempted company’s register of members is not open to inspection; |
⯀ | an exempted company does not have to hold an annual shareholder meeting; |
⯀ | an exempted company may issue negotiable or bearer shares or shares with no par value; |
⯀ | an exempted company may obtain an undertaking against the imposition of any future taxation (such undertakings are usually given for 20 years in the first instance); |
⯀ | an exempted company may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands; |
⯀ | an exempted company may register as a limited duration company; and |
⯀ | an exempted company may register as a segregated portfolio company. |
⯀ | if we do not consummate an initial business combination within 24 months from the closing of this offering, we will (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but no more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account and not previously released to us to pay our income taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of the then-outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and our board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii) to our obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law; |
⯀ | prior to the completion of our initial business combination, we may not issue additional securities that would entitle the holders thereof to (i) receive funds from the trust account or (ii) vote as a class with our public shares (a) on our initial business combination or on any other proposal presented to shareholders prior to or in connection with the completion of an initial business combination or (b) to approve an amendment to our amended and restated memorandum and articles of association to (x) extend the time we have to consummate a business combination beyond 24 months from the closing of this offering or (y) amend the foregoing provisions; |
⯀ | although we do not intend to enter into a business combination with a target business that is affiliated with our sponsor, our directors or our executive officers, we are not prohibited from doing so. In the event we enter into |
⯀ | if a shareholder vote on our initial business combination is not required by applicable law or stock exchange rule and we do not decide to hold a shareholder vote for business or other reasons, we will offer to redeem our public shares pursuant to Rule 13e-4 and Regulation 14E of the Exchange Act, and will file tender offer documents with the SEC prior to completing our initial business combination which contain substantially the same financial and other information about our initial business combination and the redemption rights as is required under Regulation 14A of the Exchange Act; |
⯀ | our initial business combination must occur with one or more target businesses that together have an aggregate fair market value of at least 80% of the net assets held in the trust account (excluding the amount of deferred underwriting discounts held in trust and taxes payable on the interest earned on the trust account) at the time of signing the agreement to enter into the initial business combination; |
⯀ | if our shareholders approve an amendment to our amended and restated memorandum and articles of association (A) that would modify the substance or timing of our obligation to provide holders of our Class A ordinary shares the right to have their shares redeemed in connection with our initial business combination or to redeem 100% of our public shares if we do not complete our initial business combination within 24 months from the closing of this offering or (B) with respect to any other provision relating to the rights of holders of our Class A ordinary shares, we will provide our public shareholders with the opportunity to redeem all or a portion of their ordinary shares upon such approval at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account and not previously released to us to pay our income taxes, if any, divided by the number of the then-outstanding public shares, subject to the limitations described herein; and |
⯀ | we will not effectuate our initial business combination solely with another blank check company or a similar company with nominal operations. |
(a) | the subscriber makes the payment for their investment from an account held in the subscriber’s name at a recognized financial institution; |
(b) | the subscriber is regulated by a recognized regulatory authority and is based or incorporated in, or formed under the law of, a recognized jurisdiction; or |
(c) | the application is made through an intermediary which is regulated by a recognized regulatory authority and is based in or incorporated in, or formed under the law of a recognized jurisdiction and an assurance is provided in relation to the procedures undertaken on the underlying investors. |
⯀ | 1% of the total number of ordinary shares then outstanding, which will equal 160,750 shares immediately after this offering (or 184,563 shares if the underwriters exercise their over-allotment option in full); and |
⯀ | the average weekly reported trading volume of the Class A ordinary shares during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. |
⯀ | the issuer of the securities that was formerly a shell company has ceased to be a shell company; |
⯀ | the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act; |
⯀ | the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form 8-K reports; and |
⯀ | at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company. |
2. | That no law which is hereafter enacted in the Islands imposing any tax to be levied on profits, income, gains or appreciations shall apply to the Company or its operations; and 3. In addition, that no tax to be levied on profits, income, gains or appreciations or which is in the nature of estate duty or inheritance tax shall be payable: |
3.2 | On or in respect of the shares, debentures or other obligations of the Company; or |
3.3 | by way of the withholding in whole or part, of any relevant payment as defined in Section 6(3) of the Tax Concessions Law (2018 Revision). |
⯀ | our sponsor, founders, officers or directors; |
⯀ | banks, financial institutions or financial services entities; |
⯀ | broker-dealers; |
⯀ | taxpayers that are subject to the mark-to-market accounting rules; |
⯀ | S-corporations; |
⯀ | tax-exempt entities; |
⯀ | governments or agencies or instrumentalities thereof; |
⯀ | insurance companies; |
⯀ | regulated investment companies; |
⯀ | real estate investment trusts; |
⯀ | controlled foreign corporations; |
⯀ | passive foreign investment companies; |
⯀ | expatriates or former long-term residents of the United States; |
⯀ | persons that actually or constructively own five percent or more of our shares; |
⯀ | persons that acquired our securities pursuant to an exercise of employee share options, in connection with employee share incentive plans or otherwise as compensation or in connection with services; |
⯀ | persons that hold our securities as part of a straddle, constructive sale, hedging, conversion or other integrated or similar transaction; or |
⯀ | U.S. Holders (as defined below) whose functional currency is not the U.S. dollar. |
⯀ | the U.S. Holder’s gain or excess distribution will be allocated ratably over the U.S. Holder’s holding period for the Class A ordinary shares; |
⯀ | the amount allocated to the U.S. Holder’s taxable year in which the U.S. Holder recognized the gain or received the excess distribution, or to the period in the U.S. Holder’s holding period before the first day of our first taxable year in which we are a PFIC, will be taxed as ordinary income; |
⯀ | the amount allocated to other taxable years (or portions thereof) of the U.S. Holder and included in its holding period will be taxed at the highest tax rate in effect for that year and applicable to the U.S. Holder; and |
⯀ | an additional tax equal to the interest charge generally applicable to underpayments of tax will be imposed on the U.S. Holder with respect to the tax attributable to each such other taxable year of the U.S. Holder. |
⯀ | a non-resident alien individual (other than certain former citizens and residents of the United States subject to U.S. tax as expatriates); |
⯀ | a foreign corporation; or |
⯀ | an estate or trust that is not a U.S. Holder; but generally does not include an individual who is present in the United States for 183 days or more in the taxable year of disposition. A U.S. Holder who is such an individual should consult its tax advisor regarding the U.S. federal income tax consequences of the sale or other disposition of our securities. |
| | Number of SHARES | |
Underwriter | | | |
Jefferies LLC | | | |
Goldman Sachs & Co. LLC | | | |
Total | | | 12,500,000 |
| | Paid by ARYA Sciences Acquisition Corp III | ||||
| | No Exercise | | | Full Exercise | |
Per Class A ordinary share(1) | | | $0.55 | | | $0.55 |
Total(1) | | | $6,875,000 | | | $7,906,250 |
(1) | $0.20 per share, or $2,500,000 in the aggregate (or $2,875,000 in the aggregate if the underwriters’ option to purchase additional shares is exercised in full), is payable upon the closing of this offering. $0.35 per share, or $4,375,000 in the aggregate (or $5,031,250 in the aggregate if the underwriters’ option to purchase additional shares is exercised in full) payable to the underwriters for deferred underwriting commissions will be placed in a trust account located in the United States as described herein. The deferred commissions will be released to the underwriters only on and concurrently with completion of an initial business combination. |
⯀ | the purchaser is entitled under applicable provincial securities laws to purchase the securities without the benefit of a prospectus qualified under those securities laws as it is an “accredited investor” as defined under National Instrument 45-106 — Prospectus Exemptions, |
⯀ | the purchaser is a “permitted client” as defined in National Instrument 31-103 — Registration Requirements, Exemptions and Ongoing Registrant Obligations, |
⯀ | where required by law, the purchaser is purchasing as principal and not as agent, and |
⯀ | the purchaser has reviewed the text above under Resale Restrictions. |
⯀ | a “sophisticated investor” under section 708(8)(a) or (b) of the Corporations Act; |
⯀ | a “sophisticated investor” under section 708(8)(c) or (d) of the Corporations Act and that you have provided an accountant’s certificate to the Company which complies with the requirements of section 708(8)(c)(i) or (ii) of the Corporations Act and related regulations before the offer has been made; |
⯀ | a person associated with the Company under Section 708(12) of the Corporations Act; or |
⯀ | a “professional investor” within the meaning of section 708(11)(a) or (b) of the Corporations Act. |
⯀ | a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or |
⯀ | a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities (as defined in Section 239(1) of the SFA) of that corporation or the beneficiaries’ rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the securities pursuant to an offer made under Section 275 of the SFA except: |
⯀ | to an institutional investor or to a relevant person defined in Section 275(2) of the SFA, or to any person arising from an offer referred to in Section 275(1A) or Section 276(4)(i)(B) of the SFA; |
⯀ | where no consideration is or will be given for the transfer; |
⯀ | where the transfer is by operation of law; |
⯀ | as specified in Section 276(7) of the SFA; or |
⯀ | as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore. |
Assets | | | |
Deferred offering costs associated with initial public offering | | | $25,000 |
Total assets | | | $25,000 |
| | ||
Liabilities and Shareholder’s Equity | | | |
Current liabilities: | | | |
Accrued expenses | | | $4,245 |
Total current liabilities | | | 4,245 |
| | ||
Commitments and Contingencies | | | |
| | ||
Shareholder’s Equity: | | | |
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding | | | — |
Class A ordinary shares, $0.0001 par value; 479,000,000 shares authorized; none issued and outstanding | | | — |
Class B ordinary shares, $0.0001 par value; 20,000,000 shares authorized; 3,593,750 shares issued and outstanding(1) | | | 359 |
Additional paid-in capital | | | 24,641 |
Accumulated deficit | | | (4,245) |
Total shareholder’s equity | | | 20,755 |
Total Liabilities and Shareholder’s Equity | | | $25,000 |
(1) | This number includes up to 468,750 shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters. |
General and administrative expenses | | | $4,245 |
Net loss | | | $(4,245) |
| | ||
Weighted average shares outstanding, basic and diluted(1) | | | 3,125,000 |
| | ||
Basic and diluted net loss per share | | | $(0.00) |
(1) | This number excludes an aggregate of up to 468,750 shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters. |
| | Ordinary Shares | | | Additional Paid-in Capital | | | Accumulated Deficit | | | Total Shareholder’s Equity | ||||||||||
| | Class A | | | Class B | | |||||||||||||||
| | Shares | | | Amount | | | Shares | | | Amount | | |||||||||
Balance - March 27, 2020 (inception) | | | — | | | $— | | | — | | | $— | | | $— | | | $— | | | $— |
Issuance of Class B ordinary shares to Sponsor(1) | | | — | | | — | | | 3,593,750 | | | 359 | | | 24,641 | | | — | | | 25,000 |
Net loss | | | — | | | — | | | — | | | — | | | — | | | (4,245) | | | (4,245) |
Balance - April 2, 2020 | | | — | | | $— | | | 3,593,750 | | | $359 | | | $24,641 | | | $(4,245) | | | $20,755 |
(1) | This number includes up to 468,750 shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters. |
Cash Flows from Operating Activities: | | | |
Net loss | | | $(4,245) |
Changes in operating assets and liabilities: | | | |
Accrued expenses | | | 4,245 |
Net cash used in operating activities | | | — |
| | ||
Net change in cash | | | — |
| | ||
Cash - beginning of the period | | | — |
Cash - end of the period | | | $— |
| | ||
Supplemental disclosure of noncash investing and financing activities: | | | |
Deferred offering costs paid by Sponsor in exchange for issuance of Class B ordinary shares | | | $25,000 |
Jefferies | | | Goldman Sachs & Co. LLC |
Item 13. | Other Expenses of Issuance and Distribution. |
SEC expenses | | | $18,659 |
FINRA expenses | | | 22,063 |
Accounting fees and expenses | | | 60,000 |
Printing and engraving expenses | | | 30,000 |
Travel and road show expenses | | | 20,000 |
Legal fees and expenses | | | 325,000 |
Nasdaq listing and filing fees | | | 55,000 |
Director & Officers liability insurance premiums(1) | | | 125,000 |
Miscellaneous | | | 344,278 |
Total | | | $1,000,000 |
(1) | This amount represents the approximate amount of annual director and officer liability insurance premiums the registrant anticipates paying following the completion of its initial public offering and until it completes a business combination. |
Item 14. | Indemnification of Directors and Officers. |
Item 15. | Recent Sales of Unregistered Securities. |
Item 16. | Exhibits and Financial Statement Schedules. |
(a) | The Exhibit Index is incorporated herein by reference. |
Item 17. | Undertakings. |
(a) | The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreements, certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. |
(b) | Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the U.S. Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. |
(c) | The undersigned registrant hereby undertakes that: |
(1) | For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. |
(2) | For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
EXHIBIT NO. | | | DESCRIPTION |
1.1 | | | Form of Underwriting Agreement.* |
3.1 | | | Memorandum and Articles of Association.* |
3.2 | | | Form of Amended and Restated Memorandum and Articles of Association.* |
4.1 | | | Specimen Ordinary Share Certificate.* |
5.1 | | | Opinion of Ogier, Cayman Islands Counsel to the Registrant.* |
10.1 | | | Form of Investment Management Trust Agreement between Continental Stock Transfer & Trust Company and the Registrant.* |
10.2 | | | Form of Registration and Shareholder Rights Agreement among the Registrant, the Sponsor and the Holders signatory thereto.* |
10.3 | | | Form of Private Placement Shares Purchase Agreement between the Registrant and the Sponsor.* |
10.4 | | | Form of Indemnity Agreement.* |
10.5 | | | Form of Administrative Services Agreement between the Registrant and the Sponsor.* |
10.6 | | | Promissory Note, dated as of April 2, 2020, issued to the Sponsor.* |
10.7 | | | Securities Subscription Agreement, dated April 2, 2020, between the Registrant and the Sponsor.* |
10.8 | | | Form of Letter Agreement among the Registrant, the Sponsor and each director and executive officer of the Registrant.* |
| | Consent of WithumSmith+Brown, PC. | |
23.2 | | | Consent of Ogier (included in Exhibit 5.1).* |
| | Power of Attorney (included on the signature page of this Registration Statement). | |
| | Consent of Todd Wider. |
* | To be filed by amendment. |
| | ARYA SCIENCES ACQUISITION CORP III | ||||
| | | | |||
| | | | |||
| | By: | | | /s/ Adam Stone | |
| | | | Name: Adam Stone | ||
| | | | Title: Chief Executive Officer |
NAME | | | POSITION | | | DATE |
/s/ Joseph Edelman | | | Chairman of the Board of Directors | | | July 21, 2020 |
Joseph Edelman | | | | | ||
| | | | |||
/s/ Adam Stone | | | Chief Executive Officer and Director (Principal Executive Officer) | | | July 21, 2020 |
Adam Stone | | | ||||
| | | | |||
/s/ Michael Altman | | | Chief Financial Officer and Director (Principal Financial and Accounting Officer) | | | July 21, 2020 |
Michael Altman | | |
/s/ WithumSmith+Brown, PC
|
|
|
|
New York, New York
|
|
July 20, 2020
|
By:
|
/s/ Todd Wider
|
|
Name:
|
Todd Wider
|